Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Allergy Thera. Share Price
  4. Allergy Thera. Share Regulatory News
  5. Director/PDMR Shareholding

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Allergy Thera. Information

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Director/PDMR Shareholding

7 May 2008 11:50

Allergy Therapeutics PLC07 May 2008 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director/PDMR Shareholding 7 May 2008: Allergy Therapeutics announces that on 7 May 2008 Mr Keith Carter, adirector of the Company, exercised share options over 575,000 ordinary shares of0.1 pence each ("Ordinary Shares") awarded pursuant to the Allergy Therapeutics2001 Share Option Plan as follows: Name of scheme: Allergy Therapeutics 2001 Share Option PlanDate of grant: 18 December 2002Date of exercise: 7 May 2008Exercise price: 5.0 penceNumber of shares exercised: 575,000 Following the above transactions Mr Carter now holds share options over1,929,055 Ordinary Shares. In addition Mr Carter holds 3,172,669 OrdinaryShares, representing 3.87 per cent. of the total voting rights of the Company. Enquiries: Allergy Therapeutics plc +44 (0) 1903 845 820Ian Postlethwaitewww.allergytherapeutics.com Financial Dynamics +44 (0) 207 831 3113David YatesBen Brewerton This information is provided by RNS The company news service from the London Stock Exchange
12345678910
Date   Source Headline
31st Mar 20267:00 amRNSInterim Results for six months ended 31 Dec 2025
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
4th Mar 20267:00 amRNSPositive Biomarker Results from PROTECT Trial
26th Feb 20267:00 amRNS-RAllergy Therapeutics presents progress at AAAAI
23rd Feb 20267:51 amRNSUpdate on funding and total voting rights
30th Jan 20268:22 amRNSChief Strategy Officer and Board appointments
29th Jan 20262:13 pmRNSResult of Annual General Meeting
28th Jan 20264:48 pmRNSGrant of Options under Long Term Incentive Scheme
19th Jan 20267:00 amRNSHalf Year Trading Update
6th Jan 20267:00 amRNSNotice of 2025 Annual General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
16th Dec 20257:00 amRNSGrassmuno® marketing authorisation in Germany
12th Dec 20257:00 amRNSAuthority for allotment of New Shares
11th Dec 20257:00 amRNSPrelim Results and publication of Annual Report
9th Dec 20257:00 amRNSPrimary Safety Endpoint Met in PROTECT trial
6th Nov 20257:22 amRNSCompany to Evaluate Dual Listing on HKEX
30th Oct 20257:00 amRNSG308 Phase III Year 2 Patient Screening Starts
29th Oct 20257:00 amRNSWarrant Exercise and Paydown of Debt
16th Oct 20257:00 amRNSFurther progress in Phase I/IIa PROTECT trial
31st Jul 20257:00 amRNS-RGrass MATA MPL Publications in Allergy Journal
21st Jul 20257:00 amRNSTrading update for the year ended 30 June 2025
11th Jul 20257:00 amRNSPDMR Dealings
13th Jun 20257:00 amRNS-RAllergy Therapeutics presents findings at EAACI
10th Jun 20257:04 amRNS-REAACI Early Career Research Award
31st Mar 20257:00 amRNSInterim Results for six months ended 31 Dec 2024
27th Mar 20257:00 amRNSAdvancement to final phase of PROTECT trial
3rd Mar 20257:00 amRNSNew Executive Long Term Incentive Awards
27th Feb 20257:00 amRNS-RPresentations at 2025 AAAAI / WAO Joint Congress
17th Feb 20257:00 amRNSGrass MATA MPL Phase III data published in Allergy
14th Feb 20257:00 amRNSGrant of Options
28th Jan 20257:00 amRNSHalf Year Trading update
22nd Jan 20257:00 amRNSPDMR Dealing and Total Voting Rights
15th Jan 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20241:41 pmRNSExercise of Options and Total Voting Rights
17th Dec 20244:19 pmRNSBlock Listing Interim Review
16th Dec 20243:33 pmRNSResult of Annual General Meeting
4th Dec 20247:00 amRNSPositive Interim Data from PROTECT Trial
27th Nov 20247:00 amRNSFirst Patient Dosed in G308 Paediatric Trial
25th Nov 20247:00 amRNSSubmission of MAA for Grass MATA MPL
21st Nov 20247:00 amRNSNotice of 2024 Annual General Meeting
6th Nov 20247:00 amRNSAudited Preliminary Results 2024
21st Oct 20247:00 amRNSCommencement of Phase III Paediatric Trial
16th Oct 20247:00 amRNSUpdate on funding
1st Oct 20247:00 amRNSUpdate on funding and preliminary results
17th Sep 20247:00 amRNSProgression of patient cohorts in PROTECT Trial
27th Aug 20247:00 amRNSUpdate on funding
22nd Jul 20247:01 amRNSTrading update for the year ended 30 June 2024
22nd Jul 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
WIX
Wickes Group P.
LSE
-0.81%
SEE
Seeing Machines
LSE
-1.08%
DWL
Dowlais
LSE
0.00%
OIG
Oryx International Growth
LSE
0.00%
GLR
Galileo Resources PLC
LSE
-2.78%
Trending
MPL
Mercantile Ports & Logistics
LSE
53.85%
PREM
Premier African Minerals
LSE
1.09%
FORG
Forgent
LSE
2.63%
HEX
Helix Exploration
LSE
-0.67%
AVCT
Avacta Group
LSE
-2.10%